MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 462815 | Name: Lodoxamide ethyl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lodoxamide ethyl is a cromolyn-like drug which prevents antigen-induced mediator release from mast cells and antigen-induced bronchoconstriction in sensitive animals and man.

Chemical Structure

Lodoxamide ethyl
Lodoxamide ethyl
CAS#53882-13-6

Theoretical Analysis

MedKoo Cat#: 462815

Name: Lodoxamide ethyl

CAS#: 53882-13-6

Chemical Formula: C15H14ClN3O6

Exact Mass: 367.0571

Molecular Weight: 367.74

Elemental Analysis: C, 48.99; H, 3.84; Cl, 9.64; N, 11.43; O, 26.10

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
U 42,718; U-42,718; U42718;
IUPAC/Chemical Name
diethyl 2,2'-((2-chloro-5-cyano-1,3-phenylene)bis(azanediyl))bis(2-oxoacetate)
InChi Key
BNTAPIYHWPPFBW-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H14ClN3O6/c1-3-24-14(22)12(20)18-9-5-8(7-17)6-10(11(9)16)19-13(21)15(23)25-4-2/h5-6H,3-4H2,1-2H3,(H,18,20)(H,19,21)
SMILES Code
CCOC(C(Nc1c(Cl)c(NC(C(OCC)=O)=O)cc(C#N)c1)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 367.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Nam SY, Park SJ, Im DS. Protective effect of lodoxamide on hepatic steatosis through GPR35. Cell Signal. 2019 Jan;53:190-200. doi: 10.1016/j.cellsig.2018.10.001. Epub 2018 Oct 7. PMID: 30304698. 2: Rodriguez-Garcia A, Macias-Rodriguez Y, Gonzalez-Gonzalez JM. Efficacy and safety of 0.1% lodoxamide for the long-term treatment of superior limbic keratoconjunctivitis. Int Ophthalmol. 2018 Jun;38(3):1243-1249. doi: 10.1007/s10792-017-0588-1. Epub 2017 Jun 10. PMID: 28602013. 3: MacKenzie AE, Caltabiano G, Kent TC, Jenkins L, McCallum JE, Hudson BD, Nicklin SA, Fawcett L, Markwick R, Charlton SJ, Milligan G. The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. Mol Pharmacol. 2014 Jan;85(1):91-104. doi: 10.1124/mol.113.089482. Epub 2013 Oct 10. PMID: 24113750; PMCID: PMC3868900. 4: Denis D, Bloch-Michel E, Verin P, Sebastiani A, Tazartes M, Helleboid L, Di Giovanni A, Lecorvec M. Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA. Br J Ophthalmol. 1998 Oct;82(10):1135-8. doi: 10.1136/bjo.82.10.1135. PMID: 9924299; PMCID: PMC1722390. 5: Schoch C. Effects of ketotifen 0.025% and lodoxamide 0.1% on eosinophil infiltration into the guinea pig conjunctiva in a model of allergic conjunctivitis. J Ocul Pharmacol Ther. 2003 Apr;19(2):153-9. doi: 10.1089/108076803321637681. PMID: 12804060. 6: Gündüz K, Uçakhan O, Budak K, Eryilmaz T, Ozkan M. Efficacy of lodoxamide 0.1% versus N-acetyl aspartyl glutamic acid 6% ophthalmic solutions in patients with vernal keratoconjunctivitis. Ophthalmic Res. 1996;28(2):80-7. doi: 10.1159/000267878. PMID: 8792357. 7: Adefule-Ositelu AO, Onakoya AO, Olasimbo OO, Adefule AK. A clinicopathological analysis of the efficacy of lodoxamide 0.1% eye drops on the conjunctiva of patients with vernal keratoconjunctivitis seen at Guinness Eye Centre, Lagos University Teaching Hospital. Niger Postgrad Med J. 2006 Mar;13(1):35-40. PMID: 16633377. 8: Desowitz RS, Palumbo NE, Perri SF, Sylvester MS. Inhibition of the adverse reaction to diethylcarbamazine in Dirofilaria immitis-infected dogs by lodoxamide ethyl. Am J Trop Med Hyg. 1982 Mar;31(2):309-12. doi: 10.4269/ajtmh.1982.31.309. PMID: 7072895. 9: Ciprandi G, Buscaglia S, Catrullo A, Paolieri F, Riccio AM, Fiorino N, Canonica GW. Antiallergic activity of topical lodoxamide on in vivo and in vitro models. Allergy. 1996 Dec;51(12):946-51. doi: 10.1111/j.1398-9995.1996.tb04499.x. PMID: 9020426. 10: Cerqueti PM, Ricca V, Tosca MA, Buscaglia S, Ciprandi G. Lodoxamide treatment of allergic conjunctivitis. Int Arch Allergy Immunol. 1994 Oct;105(2):185-9. doi: 10.1159/000236823. PMID: 7920019. 11: Katcher ML, Reed CE. Prevention of antigen-induced bronchoconstriction by lodoxamide ethyl, a new orally active antiallergic drug. J Allergy Clin Immunol. 1980 Sep;66(3):223-6. doi: 10.1016/0091-6749(80)90043-3. PMID: 7410746. 12: Verin P, Allewaert R, Joyaux JC, Piozzi E, Koliopoulos J, Bloch-Michel E; Lodoxamide Study Group. Comparison of lodoxamide 0.1% ophthalmic solution and levocabastine 0.05% ophthalmic suspension in vernal keratoconjunctivitis. Eur J Ophthalmol. 2001 Apr-Jun;11(2):120-5. doi: 10.1177/112067210101100203. PMID: 11456011. 13: Capron M, Loiseau S, Papin JP, Robertson S, Capron A. Inhibitory effects of lodoxamide on eosinophil activation. Int Arch Allergy Immunol. 1998 Jun;116(2):140-6. doi: 10.1159/000023937. PMID: 9652307. 14: Johnson HG, Griffin RL, Wright JB. The effect of lodoxamide ethyl [diethyl N,N'-(2-chloro-5-cyano-m-phenylene)dioxamate] on in vivo anaphylactic reactions. Agents Actions. 1979 Aug;9(3):235-8. doi: 10.1007/BF01966693. PMID: 115253. 15: Lee S, Allard TR. Lodoxamide in vernal keratoconjunctivitis. Ann Pharmacother. 1996 May;30(5):535-7. doi: 10.1177/106002809603000519. PMID: 8740338. 16: Frigas E, Reed CE. Effect of iodoxamide ethyl on allergy skin tests. J Allergy Clin Immunol. 1980 Apr;65(4):257-62. doi: 10.1016/0091-6749(80)90152-9. PMID: 7358942. 17: Jeffcoat MK, Williams RC, Johnson HG, Wechter WJ, Goldhaber P. Treatment of periodontal disease in beagles with lodoxamide ethyl, an inhibitor of mast cell release. J Periodontal Res. 1985 Sep;20(5):532-41. doi: 10.1111/j.1600-0765.1985.tb00837.x. PMID: 2934538. 18: Das D, Khan M, Gul A, Alam R. Safety and efficacy of lodoxamide in vernal keratoconjunctivitis. J Pak Med Assoc. 2011 Mar;61(3):239-41. PMID: 21465936. 19: Akman A, Irkeç M, Orhan M. Effects of lodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis. Eye (Lond). 1998;12 ( Pt 2):291-5. doi: 10.1038/eye.1998.67. PMID: 9683957. 20: Park SJ, Lee SJ, Nam SY, Im DS. GPR35 mediates lodoxamide-induced migration inhibitory response but not CXCL17-induced migration stimulatory response in THP-1 cells; is GPR35 a receptor for CXCL17? Br J Pharmacol. 2018 Jan;175(1):154-161. doi: 10.1111/bph.14082. Epub 2017 Dec 8. PMID: 29068046; PMCID: PMC5740256.